- Home
- GLTO vs ONVO Comparison
GLTO vs ONVO Comparison
Compare GLTO & ONVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- ONVO
- Stock Information
- Founded
- GLTO 2011
- ONVO 2007
- Country
- GLTO Denmark
- ONVO United States
- Employees
- GLTO N/A
- ONVO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- ONVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLTO Health Care
- ONVO Health Care
- Exchange
- GLTO Nasdaq
- ONVO Nasdaq
- Market Cap
- GLTO 6.5M
- ONVO 5.3M
- IPO Year
- GLTO 2020
- ONVO N/A
- Fundamental
- Price
- GLTO $4.51
- ONVO $0.37
- Analyst Decision
- GLTO Buy
- ONVO
- Analyst Count
- GLTO 1
- ONVO 0
- Target Price
- GLTO $10.00
- ONVO N/A
- AVG Volume (30 Days)
- GLTO 14.7K
- ONVO 103.2K
- Earning Date
- GLTO 03-07-2025
- ONVO 02-19-2025
- Dividend Yield
- GLTO N/A
- ONVO N/A
- EPS Growth
- GLTO N/A
- ONVO N/A
- EPS
- GLTO N/A
- ONVO N/A
- Revenue
- GLTO N/A
- ONVO $122,000.00
- Revenue This Year
- GLTO N/A
- ONVO $59.08
- Revenue Next Year
- GLTO N/A
- ONVO $18.24
- P/E Ratio
- GLTO N/A
- ONVO N/A
- Revenue Growth
- GLTO N/A
- ONVO N/A
- 52 Week Low
- GLTO $4.24
- ONVO $0.32
- 52 Week High
- GLTO $23.50
- ONVO $1.74
- Technical
- Relative Strength Index (RSI)
- GLTO 39.75
- ONVO 49.60
- Support Level
- GLTO $4.39
- ONVO $0.33
- Resistance Level
- GLTO $4.84
- ONVO $0.40
- Average True Range (ATR)
- GLTO 0.31
- ONVO 0.03
- MACD
- GLTO 0.00
- ONVO 0.00
- Stochastic Oscillator
- GLTO 26.73
- ONVO 61.25
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About ONVO Organovo Holdings Inc.
Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.